Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives $20.00 Average Price Target from Analysts

Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) have earned an average recommendation of “Moderate Buy” from the five analysts that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, two have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $20.00.

Several brokerages have commented on ENTA. HC Wainwright reaffirmed a “buy” rating and issued a $27.00 price objective on shares of Enanta Pharmaceuticals in a research report on Thursday, October 10th. JMP Securities reissued a “market outperform” rating and set a $22.00 target price on shares of Enanta Pharmaceuticals in a research note on Wednesday, October 9th. JPMorgan Chase & Co. decreased their price objective on shares of Enanta Pharmaceuticals from $11.00 to $10.00 and set an “underweight” rating for the company in a report on Tuesday, August 6th. Finally, Evercore ISI upgraded shares of Enanta Pharmaceuticals to a “strong-buy” rating in a research note on Tuesday, August 6th.

Institutional Trading of Enanta Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Allspring Global Investments Holdings LLC purchased a new stake in Enanta Pharmaceuticals in the second quarter valued at about $35,000. State Board of Administration of Florida Retirement System purchased a new stake in shares of Enanta Pharmaceuticals during the 1st quarter worth about $118,000. Quest Partners LLC grew its holdings in Enanta Pharmaceuticals by 511.2% in the second quarter. Quest Partners LLC now owns 11,588 shares of the biotechnology company’s stock valued at $150,000 after purchasing an additional 9,692 shares during the period. Virtu Financial LLC purchased a new stake in Enanta Pharmaceuticals in the 1st quarter worth $191,000. Finally, American Century Companies Inc. boosted its holdings in Enanta Pharmaceuticals by 35.4% in the 2nd quarter. American Century Companies Inc. now owns 27,892 shares of the biotechnology company’s stock worth $362,000 after buying an additional 7,287 shares during the last quarter. Institutional investors own 94.99% of the company’s stock.

Enanta Pharmaceuticals Trading Up 2.4 %

Enanta Pharmaceuticals stock opened at $11.31 on Friday. Enanta Pharmaceuticals has a 12-month low of $8.08 and a 12-month high of $17.80. The firm has a 50-day moving average price of $11.89 and a 200-day moving average price of $13.14. The firm has a market capitalization of $239.53 million, a PE ratio of -1.81 and a beta of 0.58.

Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its quarterly earnings data on Monday, August 5th. The biotechnology company reported ($1.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.43) by $0.36. The business had revenue of $17.97 million during the quarter, compared to the consensus estimate of $17.44 million. Enanta Pharmaceuticals had a negative net margin of 160.27% and a negative return on equity of 63.75%. The firm’s quarterly revenue was down 4.9% compared to the same quarter last year. During the same quarter last year, the firm earned ($1.27) earnings per share. As a group, sell-side analysts predict that Enanta Pharmaceuticals will post -5.3 earnings per share for the current fiscal year.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.